CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade. Smithy JW, Luke JJ. Clin Cancer Res 2023;29:2345-2347.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Smithy JW, Luke JJ. CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade. Clin Cancer Res 2023;29:2345-2347.
PMID: 37097465